

Reimbursement and clinic reference guide

Effective 2024

Barostim Patient Flow

Patient identification · ICD consult HF hospitalization · HF diagnostic alert · EMR screening Patient assessment · Symptomatic despite GDMT • Recent echo (LVEF ≤ 35%) Baseline NT-proBNP (< 1600 pg/mL) May require medical optimization and re-test · Consider carotid doppler Prior authorization · CVRx Patient Access Support · Submit required documentation (NYHA class, EKG, Echocardiogram, NT-proBNP) Pre-implant consultation · Confirm carotid doppler (< 50% stenosis & anatomy) **Implant** · CVRx rep attendance · Consider device rep attendance for other implanted devices Wound check • Implant + 1 week Titration phase · CVRx rep attendance Typically three titration visits (1/month) • Depending on the patient, the titration phase can extend through 3-6 months Routine follow-up · Every 6 months

Vascular SurgeonCT SurgeonElectrophysiologist

Cardiologist HF Specialist Electrophysiologist

Patient assessment

Barostim indications4

C	NYHA III or NYHA II	(with recent NYHA III)	despite treatment with GDMT*	(medications and devices)
•		(,	(

LVEF ≤ 35%

NT-proBNP < 1600 pg/mL</p>

Barostim delivers Baroreflex Activation Therapy for improvement of patients' heart failure functional status, six-minute hall walk, and quality of life.

Contraindications

- · Been assessed to have bilateral carotid bifurcations located above the level of the mandible
- · Baroreflex failure or autonomic neuropathy
- · Uncontrolled, symptomatic cardiac bradyarrhythmias
- Carotid atherosclerosis that is determined by ultrasound or angiographic evaluation greater than 50%. Ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation
- Known allergy to silicone or titanium
- · NOTE: Boston Scientific's S-ICD device is contraindicated for patients with unipolar pacing devices.
- · Barostim uses unipolar stimulation.

^{*}Guideline directed medical therapy (GDMT) according to 2022 AHA/ACC/ESC guidelines

^{1.} Yancy CM, et al. Circulation. 2013;128: 2013;128:e240-e327;

 $^{2.\} https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P180050.\ Accessed\ March\ 30,\ 2021;$

³ CVRx data on file

^{4.} Instructions for Use 900133-001 Rev. D available at www.cvrx.com/ifu

Prior authorization

Barostim requires prior authorization approvals based on the patient medical necessity criteria.

CVRx offers a Patient Access Support to help.

CVRx Prior Authorization Program provides case-by-case support for providers who perform Barostim implantation procedures.

It is a HIPAA compliant entity and offers assistance for the following services:

- 1. Coding and coverage information
- 2. Eligibility and benefit verification
- 3. Prior authorization
- 4. Pre-determination or certification
- 5. Pre and post service appeals

To enroll in the CVRx Prior Authorization Program service or submit a request online:

www.cvrx.com/healthcare-professionals/reimbursement

Contact the CVRx helpline for copies of the forms or with any questions:

Email: reimbursement@cvrx.com

Phone: 763-416-2344 Fax: 855-710-7053

Barostim™ titration protocol

BeAT-HF, the clinical trial underlying approval of Barostim therapy, is predicated upon increasing the output of the Barostim device over the course of the first 3-6 months of post-implant office visits to reach therapy stabilization. For most of the patient programming in the trial, therapy was stabilized in 3-5 visits between 2-4 months. The distribution graph below, Fig. 1, reflects the programmed amplitudes in BeAT-HF, and thus the recommended Barostim programming protocol.




Fig.1 BeAT-HF clinical trial programmed amplitudes showing Median and inner quartile range (therapy amplitude normalized to 40Hz, 125uS)

Absent alternative physician orders addressing individual patient needs, CVRx field representatives will assist in programming therapy amplitudes within this protocol, i.e., the shaded blue area of Fig 1. The purpose of this protocol is to program an incrementally higher therapy output at each titration visit to reach stabilization in 2-4 months to emulate the benefits experienced in BeAT-HF.

Programming protocol:

- 1. Obtain resting baseline blood pressure (BP) and heart rate (HR)
- 2. Slowly increase amplitude by 0.2 0.4mA increments (do not exceed output increases of 5mA per titration visit)
- 3. Record any observed symptoms (e.g., extraneous stimulation, dizziness, tingling, etc.) in the programmer's Therapy Response Log corresponding to the setting producing the symptoms
- 4. At end of session, (i) set therapy to an amplitude at least 1mA below symptoms of extraneous stimulation; (ii) document a 1mA stimulation buffer; and (iii) take BP for final session notes
- 5. Repeat at each titration visit until therapy threshold is consistent

Access to BP measurements is recommended through use of either an automatic blood pressure cuff or facility staff taking manual BP measurements during the titration session. Accuracy and consistency are improved by properly trained facility staff placing an automatic cuff on the patient's arm and leaving it in the same location for the duration of the titration session or having a facility staff member take manual measurements. To facilitate this, CVRx personnel may carry an automatic blood pressure cuff that, with the assistance of medical personnel to place the cuff, can be used during the titration session.

Follow-up

Routine follow-up phase

Once a patient has completed their titration phase, they enter into the routine follow-up phase.

Timing

- Every six months patients should return to their doctor's office for a check of the battery status and lead impedance.
- · The Barostim therapy generator is designed to have an average battery life of 5 years with no charging required.

Unscheduled or urgent device checks

- Unlike pacemakers or ICDs, Barostim is not providing beat-to-beat life supporting therapy and a malfunction should not be life threatening.
- However, on rare occasions if the patient is experiencing stimulation in the neck, the therapy can be suspended
 with a magnet. Therapy will remain off as long as the magnet is in place. Therapy adjustments can then be made
 when programming is convenient.

CVRx field representatives are available to support device follow-ups and to train staff to perform routine device status checks.

Reimbursement

Reimbursement information provided by CVRx is gathered from 3rd party sources and is presented for illustrative purposes only. This information does not constitute legal or reimbursement advice. CVRx makes no representation or warranty regarding this information or its completeness, accuracy, timeliness or applicability with any particular patient. CVRx specifically disclaims liability or responsibility for the results or consequences of any actions taken in reliance on information in this document. CVRx encourages providers to submit accurate and appropriate claims for services. Laws, regulations and payer policies concerning reimbursement are complex and change frequently. Providers are responsible for making appropriate decisions related to coding and reimbursement submissions. Accordingly, CVRx recommends that customers consult with their payers, reimbursement specialists and/or legal counsel regarding coding, coverage and reimbursement matters.

Checklist for physician billing submissions

- In the claim form Item 19, or on the electronic form 837P-Loop, REF02, REF01=P4, enter a crosswalk CPT code I and verbiage around the expected reimbursement for that code in the dollar amount. (See example on Page 9)
- Paper claim CMS 1500 or electronic equivalent. Please ensure the Prior Authorization number is included in every claim submitted to commercial insurance providers.
- Detailed medical notes (operative report) which capture both the procedural information that documents the time and complexity of the work associated with the service and the patient's medical condition

Checklist for facility billing submissions

- O Please ensure the Prior Authorization number is included in every claim submitted to commercial insurance providers.
- Please ensure Barostim specific procedure codes are used for both outpatient (CPT 0266T and C1825) or inpatient coding (0JH60MZ and 03HK3MZ)
- UB-04 (outpatient or inpatient) or electronic equivalent

Contact CVRx with any questions:

Email: reimbursement@cvrx.com

Phone: 763-416-2344

System implant - diagnosis codes

ICD-10-CM	Descriptor	CC	MCC
150.21	Acute systolic (congestive) heart failure		Χ
150.22	Chronic systolic (congestive) heart failure	Х	
150.23	Acute on chronic systolic (congestive) heart failure		X
150.3	Diastolic (congestive) heart failure	Х	
I50.31	Acute diastolic (congestive) heart failure		X
150.32	Chronic diastolic (congestive) heart failure	Х	
150.33	Acute on chronic diastolic (congestive) heart failure		X
150.4	Unspecified combined systolic (congestive) and diastolic (congestive) heart failure	Χ	
150.41	Acute combined systolic (congestive) and diastolic (congestive) heart failure		Х
150.42	Chronic combined systolic (congestive) and diastolic (congestive) heart failure	Χ	
150.43	Acute on chronic combined systolic (congestive) and diastolic (congestive) heart failure		Х

System implant - physician billing

Physician system implant code (this code is used for billing)


CPT® code	Descriptor
0266T	Implantation or replacement of carotid sinus baroreflex activation device; total system

Barostim system implant is reported with Category III CPT codes. When submitting information system codes, providers may choose to reference a comparative Category I CPT procedure code with similar or equivalent resources (i.e. RVUs) to the Barostim implant in the claims form box 19.

Example Comparative codes (these codes are examples, they are not billed)

Comparative code	Descriptor	Work RVU
35301	Thromboendarterectomy,	21.16
64582	Open implantation of hypoglossal nerve neurostimulator array, pulse generator, and distal respiratory sensor electrode or electrode array	14

System implant physician billing sample



System implant

For an initial "system implant" (full device – Generator and Lead at the same time) use the following product numbers:

• 100069-202, Barostim Neo2 Neurostimulator System IPG Model CSL Comb Kit

This procedure is always billed using **C1825** - Generator, neurostimulator (implantable), non-rechargeable with carotid sinus baroreceptor stimulation lead(s).

Any (single part below) **replacements** are billed using **C1767** (Generator) and **C1778** (Lead) – see crosswalk below and more on page 15 under Replacement

100065-202, Barostim NEO2 Model 2104 **IPG** (only) 100063-212, Barostim Neo CSL Kit Model 1036 SH (**lead** only)

Procedure	Descriptor	CPT® code	HCPCS code	Item #
Initial Barostim System Implant (Kit) De novo implant only	Implantation or replacement of carotid sinus baroreflex activation device; total system	0266T	C1825	100069-202, Barostim Neo2 Neurostimulator System IPG Model CSL Comb Kit
Battery replacement only (Barostim)	Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only	0268T	C1767	100065-202, Barostim NEO2 Model 2104 IPG (only)
Lead replacement only	Implantation or replacement of carotid sinus baroreflex activation device; lead only, unilateral	0267T	C1778	100063-212, Barostim Neo CSL Kit Model 1036 SH (lead only)

Contact CVRx Reimbursement team for initial chargemaster set up at 763-416-2344 or reimbursement@cvrx.com.

System implant - outpatient hospital billing


CPT® code	Descriptor	Status indicator	APC
0266T	Implantation or replacement of carotid sinus baroreflex activation device; total system	S	1580

S - Procedure or Service, Not Discounted When Multiple. Paid under OPPS; separate APC payment.

HCPCS code	Descriptor	APC
C1825	Generator, neurostimulator (implantable), non-rechargeable with carotid sinus baroreceptor stimulation lead(s)	2030

Contact the CVRx Reimbursement team for initial chargemaster set up at 763-416-2344 or reimbursement@cvrx.com.

Outpatient UB-04 sample




System implant - inpatient hospital billing

ICD-10-PCS procedure code	Descriptor	Typical MS-DRG assignment	
0JH60MZ AND	Insertion of stimulator generator into chest subcutaneous tissue and fascia, open approach	252	with MCC
03HK3MZ	Insertion of stimulator lead into right internal carotid artery, percutaneous approach	253	with CC
OR 03HL3MZ	Insertion of stimulator lead into left internal carotid artery, percutaneous approach	254	without CC/MCC

Contact CVRx Reimbursement team for initial chargemaster set up at 763-416-2344 or reimbursement@cvrx.com.

Inpatient UB-04 sample



Follow-up - physician billing

Possible **primary diagnosis** codes for interrogation and programming. Possible **secondary diagnosis** codes for interrogation and programming are Heart Failure diagnosis codes (see page 3)

Code	Descriptor
Z45.09 Encounter for adjustment and management of other cardiac device	
Z45.89	Encounter for adjustment and management of other implanted devices

Follow up visits or services may be billed independently from the Barostim device interrogation (with or without programming) and evaluation visits.

Part 1 Physician billing: follow up visit CPT codes

Category III CPT codes are not assigned global periods, so any subsequent visits or services may be billed independently from the initial procedure. The following E/M CPT codes may be used to report follow-up visits. If device interrogation/programming is also performed, the -25 modifier may be added to the E/M code to indicate that it is a separate service.

CPT® code³	Descriptor
99211	Office or other outpatient visit for the evaluation and management of an established patient, Typically, 5 minutes are spent performing or supervising these services.
99212	Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A problem focused history; A problem focused examination; Straightforward medical decision making. Typically, 10 minutes are spent face-to-face with the patient and/or family.
99213	Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: An expanded problem focused history; An expanded problem focused examination; Medical decision making of low complexity. Typically, 15 minutes are spent face-to-face with the patient and/or family
99214	Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A detailed history; A detailed examination; Medical decision making of moderate complexity. Typically, 25 minutes are spent face-to-face with the patient and/or family.
99215	Office or other outpatient visit for the evaluation and management of an established patient, which requires at least 2 of these 3 key components: A comprehensive history; A comprehensive examination; Medical decision making of high complexity. Typically, 40 minutes are spent face-to-face with the patient and/or family.

Follow-up - physician coding and billing (continued)

Part 2 Physician billing: follow-up visit device interrogation with programming

Whenever programming is performed, it is essential that physicians individually document the specific parameters changed for coding purposes. Barostim device interrogation is reported with Category III CPT codes. When submitting claim information, providers may choose to reference a comparative Category I CPT procedure code with similar or equivalent resources (i.e. RVUs) to the Barostim implant in the claims form box 19.

This code is used for billing:

CPT 0273T - Interrogation device evaluation with programming

Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report; with programming

Example Comparative codes (these codes are examples, they are not billed):

Comparative codes	Descriptor	Code	RVU
Programming device evaluation (in person) with iterative adjustment of the implantable	multiple lead transvenous implantable defibrillator system	93284	3.14 T 1.25 W
device to test the function of the device and select optimal	multiple lead pacemaker system	93281	2.50 T .85 W
permanent programmed values with analysis, review and report by a physician or other qualified	single lead transvenous implantable defibrillator system	93282	2.37 T .85 W
health care professional			

This code is used for billing:


CPT 0272T - Interrogation device evaluation

Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day)

Example Comparative codes (these codes are examples, they are not billed):

Comparative codes	Descriptor	Code	RVU
Interrogation device evaluation (in person) with analysis, review and report by a physician or	single, dual, or multiple lead transvenous implantable defibrillator system, including analysis of heart rhythm derived data elements	93289	2.15 T .75 W
other qualified health care professional, includes connection, recording and	implantable subcutaneous lead defibrillator system	93261	2.08 T .74 W
disconnection per patient encounter	single, dual, or multiple lead pacemaker system, or leadless pacemaker system	93288	1.68 T .43 W

Follow up and device titration physician billing sample



Additional reimbursement information

1500 Form locator

Item number	Title	Notes
Item 19	Additional Claim Information	Enter crosswalk CPT code I and verbiage around the expected reimbursement for that code in dollar amount
Item 21 (1-4)	Diagnosis or Nature of Illness or Injury	Enter the ICD-10 CM diagnosis codes to identify the patient's diagnosis and/or condition
Item 23	Prior Authorization Number	Enter payer's prior authorization number (if obtained prior to the procedure)
Item 24D	Procedures, Services or Supplies	Enter CPT codes for each procedure or service rendered, with one CPT code in each line. Include modifiers if needed, eg80, if assistant surgeon
Item 24E	Diagnosis Pointer	Point the services in 24 D to the diagnosis codes listed in 21 1-4

Generator replacement - physician billing

Physician generator replacement code (this code is used for billing)

CPT® code³

Descriptor

Battery replacement


Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)

Barostim generator replacement is reported with Category III CPT codes. When submitting claim information, providers may choose to reference a comparative Category I CPT procedure code with similar or equivalent resources (i.e. RVUs) to the Barostim implant in the claims form box 19.

Example Comparative codes (these codes are examples, they are not billed)

Comparative	e code	Work RVU
61885	Insertion or replacement of cranial neurostimulator pulse generator or receiver, direct or inductive coupling; with connection to a single electrode array	6.05

Generator replacement physician billing sample



Generator replacement - outpatient hospital billing

CPT® code³	Descriptor	Status indicator	APC	
Battery replace	cement			
0268T	Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)		5465	

HCPCS level II device codes

The following HCPCS Level II codes should be used for cost reporting purposes when reporting Barostim generator replacement. In general, C-codes are used for billing Medicare and L-codes are used for billing private payers, although some private payers may also accept C-codes.

HCPCS⁵ code	Descriptor
Battery and lea	ad replacement
C1767	Generator, neurostimulator (implantable), non-rechargeable
C1778	Lead, neurostimulator (implantable)
L8686	Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension
L8680	Implantable neurostimulator electrode, each

Generator replacement outpatient UB-04 sample

31 COI	OCCUP	RRENCE DATE	32 C	DCCURRENCE DATE	33 CODE	OCCURRENCE DATE	34 CODE	OCCURRENCE DATE	35 CODE	OCCUF FROM	RRENCE SPA //	N THROUGH	36 CODE	OCCURREN FROM	CE SPAN	i Through	37		
38	_				_	•	'	•	3	9 \	ALUE CODE	S	40 CODE	VALUE CODES AMOUNT		41 CODE	VALUE CODES AMOUNT		٦
	ATIENT ATIENT	NAME ADDRESS							a b c		,,,,,,			7 8 10 10 10 10 10 10 10 10 10 10 10 10 10			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
42 R	EV. CD.	43 DESCRIPTIO	ON				44 HCPC	S / RATE / HIPPS COD	E	45 SERV	DATE	46 SERV. UNIT	3	47 TOTAL CHARGES		48 NON-0	COVERED CHARGES	49	٦
01	30	EKG										#		\$XXXX	(XX		:		٦
02	50	PHARMACY	,									#		\$XXXXX	XX		:		
02	58	IV SOLUTIO	N									#		\$XXXXX	(XX		:		
02	70	MEDICAL / S	SURGICA	AL SUPPLIES								#		\$XXXXX	(XX		:		1
02	78	OTHER DEV	/ICE / IM	PLANT				C1767		01	012024	1		\$XXXX	XX		:		1
03	60	OPERATING	ROOM					0268T		01	012024	1		\$XXXXX	XX				1
03	70	ANESTHES	IA									#		\$XXXXX	XX		:		
07	10	RECOVERY	ROOM									#		\$XXXXX	(XX		:		1
																	:		7

Ambulatory surgery center

Procedures involving the Barostim System may be also performed in the Ambulatory Surgery Centers (ASC). The following CPT codes may be used as a guide for Ambulatory Surgery Center (ASC) reporting.

CPT® code³	Descriptor	ASC payment indicator
Insertion/Re	placement	
0266T	Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)	J8
0268T	Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)	J8
Revision/Re	moval	
0269T	Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)	G2
0270T	Revision or removal of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)	G2
0271T	Revision or removal of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)	G2

J8 – Device intensive procedure, paid at adjusted rate

G2 - Non office-based surgical procedure added in CY 2008 or later; payment based on OPPS relative payment weight

Reimbursement appendix

CPT® code³	Descriptor	Status indicator	APC
0266T	Implantation or replacement of carotid sinus baroreflex activation device; total system	S	1580
0267T	Implantation or replacement of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)	J1	5461
0268T	Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)	J1	5465
0269T	Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)	Q2	5432
0270T	Revision or removal of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)	J1	5461
0271T	Revision or removal of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)	J1	5461
0272T	Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day)	S	5721
0273Т	Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report; with programming	S	5721

Hospital Outpatient Status Indicator:

J1- Hospital Part B services paid through a Comprehensive APC (C-APC). Comprehensive APCs (C-APCs) were established for certain payment groups (e.g., device intensive) whereby Medicare only reimburses a single C-APC on a date of service.

Q2- Paid under OPPS; Addendum B displays APC assignments when services are separately payable.

S- Procedure or Service, Not Discounted When Multiple; *Medicare rate for 2024

CVRx contacts

Contact

Technical support (24/7) Phone: +1 763-416-2343

Reimbursement

Phone: 763-416-2344 Fax: 855-710-7053

Email: reimbursement@cvrx.com

Prior authorization Email: c-pas@cvrx.com

www.cvrx.com/reimbursement

Local Team	
Sales	
Clinical support	
Training	

References:

Physician Billing

- 1 https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P180050
- 2 ICD-10-CM 2024. American Medical Association, Chicago, IL.
- 3 Current Procedural Terminology 2024, American Medical Association. Chicago, IL. CPT is a registered trademark of the American Medical Association. Current Procedural Terminology (CPT®) is copyright American Medical Association. All Rights Reserved. Applicable FARS/ DFARS apply.
- 4 National Uniform Claim Committee, 1500 Health Insurance Claim Form Reference Instruction Manual. Version 9.15/14.1

Facility Billing

- 1 Current Procedural Terminology 2024, American Medical Association. Chicago, IL. CPT is a registered trademark of the American Medical Association. Current Procedural Terminology (CPT®) is copyright American Medical Association. All Rights Reserved. Applicable FARS/DFARS apply.
- 2 ICD-10-PCS and ICD-10-CM 2024. American Medical Association, Chicago, IL.
- 3 2024 IPPS Final Rule 1785-F
- 4 2024 OPPS and ASC Final Rule CMS-1786-FC.
- 5 2024 HCPCS Level II Expert. AAPC, Salt Lake City, UT.
- 6 https://www.cms.gov/newsroom/fact-sheets/cy-2024-medicare-hospital-outpatient-prospective-payment-system-and-ambulatory-surgical-center-0

CAUTION: Federal law restricts this device to sale by or on the order of a physician. See Instructions for Use 900133-001 for a complete instruction for use and a description of indications, contraindications, warnings, precautions and adverse events.

Barostim is indicated for patients who are NYHA Class III or Class II (who had a recent history of Class III) despite treatment with guideline-directed medical therapies (medications and devices), have a left ventricular ejection fraction of \leq 35%, and a NT-proBNP <1600 pg/ml. Barostim delivers Baroreflex Activation Therapy for improvement of patients' heart failure functional status, six-minute hall walk, and quality of life.

Patients are contraindicated if they have been assessed to have bilateral carotid bifurcations located above the level of the mandible, baroreflex failure or autonomic neuropathy, uncontrolled symptomatic cardiac bradyarrhythmias, carotid atherosclerosis that is determined by ultrasound or angiographic evaluation greater than 50%, ulcerative plaques in the carotid artery as determined by ultrasound or angiographic evaluation, known allergy to silicone or titanium.

Warnings include: only trained physicians may use this system, prescribing physicians should be experienced in the diagnosis and treatment of heart failure and should be familiar with the use of this system, monitor blood pressure and heart rate during Carotid Sinus Lead placement and when adjusting stimulation parameters intra-operatively, post-implantation, program the system to avoid the following: heart rate falls below 50 beats per minute (BPM), or systolic pressure falls below 90 mmHg, or diastolic blood pressure falls below 50 mmHg, or problematic adjacent tissue stimulation is noted, or undesirable interaction indicated by monitoring of any other implanted electrical device (see "Device Interaction Testing" in Section 10), or any other potentially hazardous patient responses are observed. Improper system implantation could result in serious injury or death. Do not use diathermy therapy including shortwave, microwave, or therapeutic ultrasound diathermy on patients implanted with the system. Patients should be counseled to stay at least 15 cm (6 inches) away from devices with strong electrical or magnetic fields such as strong magnets, loudspeaker magnets, Electronic Article Surveillance (EAS) system tag deactivators, are welders, induction furnaces, and other similar electrical or electromechanical devices. This would include not placing items such as earphones in close proximity to the implanted pulse generator. The IPG may affect the operation of other implanted devices such as cardiac defibrillators, pacemakers, or neurological stimulation systems. For patients who currently have an implanted electrical medical device, physicians must verify compatibility with the implanted device during implantation of the system. Contralateral implant of the Barostim NEO IPG may help to reduce potential interactions. Interactions are more likely in devices that contain a sensing function, such as an implantable cardiac defibrillator or pacemaker. If an interaction is observed, the Barostim NEO IPG should be program

Precautions include: the system should be implanted and programmed carefully to avoid stimulation of tissues near the electrode or in the area of the IPG pocket. Such extraneous stimulation could involve the following: the regional nerves, causing laryngeal irritation, difficulty swallowing, or dyspnea, the cervical musculature, causing intermittent contraction, skeletal muscles, causing intermittent contraction around the IPG pocket. Proper sterile technique during implantation should be practiced and aggressive pre-operative antibiotics are recommended. Infections related to any implanted device are difficult to treat and may necessitate device explantation.

It is anticipated that subjects will be exposed to operative and post-operative risks similar to related surgical procedures involving the neck and/or a pacemaker implant. These risks and potential risks of chronic device based baroreflex activation may include, but are not limited to: stroke, transient ischemic attack (TIA), systemic embolization, surgical or anesthetic complications, infection, wound complications, arterial damage, pain, nerve damage/stimulation, hypotension, hypotension, hypotension, exacerbation of heart failure, cardiac arrhythmias, tissue erosion/IPG migration, injury to baroreceptors, fibrosis, allergic reaction, general injury to user or patient, need for reoperation, secondary operative procedure, and death. Patients implanted with the system may receive Magnetic Resonance Imaging (MRI) only when all MR Conditional safety parameters are met as listed in the instructions for use.

CVRx, Barostim, Barostim NEO, Barostim NEO2, BATwire, "Outsmart the heart" and Barohub are all trademarks of CVRx, Inc. ©2024 CVRx, Inc. All rights reserved. All other trademarks are property of their respective owners.

For a list of all potential benefits and risks go to www.cvrx.com/benefit-risk-analysis/ For a list of all applicable patents, see www.cvrx.com/patent-marking.

CVRx. Inc. 9201 West Broadway Ave., Suite 650 Minneapolis, MN 55445 Phone: (763) 416-2840

Fax: (763) 416-2841 www.cvrx.com

